mhurhangee/ep-ind-claims huggingface dataset:
A medical device system for detecting an epileptic seizure based upon a patient's cardiac signal and body movement, comprising: a heart beat sensor for sensing a cardiac signal indicative of the patient's heart beats; a motion sensor for sensing a kinetic signal indicative of a body movement of the patient; a detection module for detecting an epileptic seizure based upon the cardiac signal and the kinetic signal; wherein the detection module comprises a program storage device having an algorithm for detecting an epileptic seizure, said algorithm when executed being capable of performing a method comprising the steps of detecting a possible epileptic seizure based upon changes in the patient's cardiac signal; calculating at least one kinetic score for said kinetic signal, said at least one kinetic score being indicative of a correlation of said kinetic signal with an epileptic seizure; confirming the detection of the possible epileptic seizure if the kinetic score is indicative of a high correlation with an epileptic seizure; and overriding the detection of the possible epileptic seizure if the kinetic score is indicative of a low correlation with an epileptic seizure; and providing an output indicative of the epileptic seizure if the detecting is confirmed; and further comprising an epileptic event classification module for classifying said epileptic seizure as a tonic-clonic, simple partial or complex partial seizure based upon at least one of said cardiac signal and said kinetic signal. a heart beat sensor for sensing a cardiac signal indicative of the patient's heart beats; a motion sensor for sensing a kinetic signal indicative of a body movement of the patient; a detection module for detecting an epileptic seizure based upon the cardiac signal and the kinetic signal; wherein the detection module comprises a program storage device having an algorithm for detecting an epileptic seizure, said algorithm when executed being capable of performing a method comprising the steps of detecting a possible epileptic seizure based upon changes in the patient's cardiac signal; calculating at least one kinetic score for said kinetic signal, said at least one kinetic score being indicative of a correlation of said kinetic signal with an epileptic seizure; confirming the detection of the possible epileptic seizure if the kinetic score is indicative of a high correlation with an epileptic seizure; and overriding the detection of the possible epileptic seizure if the kinetic score is indicative of a low correlation with an epileptic seizure; and providing an output indicative of the epileptic seizure if the detecting is confirmed; and further comprising an epileptic event classification module for classifying said epileptic seizure as a tonic-clonic, simple partial or complex partial seizure based upon at least one of said cardiac signal and said kinetic signal.
A piezoelectric microblower comprising: a vibrating plate that is driven in a bending mode by applying a voltage of a predetermined frequency to a piezoelectric element; and a blower body that fixes both ends or the periphery of the vibrating plate and forms a blower chamber between the blower body and the vibrating plate, an opening being provided in a part of the blower body facing a central portion of the vibrating plate; characterised in that, in a part of the blower chamber corresponding to the central portion of the vibrating plate, a partition is provided around the opening and thereby a resonance space is formed inside of the partition and a size of the resonance space is set such that the driving frequency of the vibrating plate and the Helmholtz resonance frequency of the resonance space correspond to each other. a vibrating plate that is driven in a bending mode by applying a voltage of a predetermined frequency to a piezoelectric element; and a blower body that fixes both ends or the periphery of the vibrating plate and forms a blower chamber between the blower body and the vibrating plate, an opening being provided in a part of the blower body facing a central portion of the vibrating plate; characterised in that, in a part of the blower chamber corresponding to the central portion of the vibrating plate, a partition is provided around the opening and thereby a resonance space is formed inside of the partition and a size of the resonance space is set such that the driving frequency of the vibrating plate and the Helmholtz resonance frequency of the resonance space correspond to each other.
An automatic dishwashing detergent composition comprising; a) a subtilisin variant having the amino acid sequence set forth in SEQ ID NO 1, and b) at least one additional ingredient selected from; i) bleaches selected from percarbonates, persulphates and organic peracids, ii) aminocarboxylates, or iii) sulphonated polymers, or iv) organophosphonic acids or salts thereof, and mixtures thereof. a) a subtilisin variant having the amino acid sequence set forth in SEQ ID NO 1, and b) at least one additional ingredient selected from; i) bleaches selected from percarbonates, persulphates and organic peracids, ii) aminocarboxylates, or iii) sulphonated polymers, or iv) organophosphonic acids or salts thereof, and mixtures thereof. i) bleaches selected from percarbonates, persulphates and organic peracids, ii) aminocarboxylates, or iii) sulphonated polymers, or iv) organophosphonic acids or salts thereof, and mixtures thereof.
A method comprising: (a) contacting a sample with a template polynucleotide, under conditions whereby a target polynucleotide in the sample hybridizes to the template polynucleotide, wherein the template polynucleotide comprises a first segment that is hybridizable to the target polynucleotide and a second segment that does not hybridize to the target polynucleotide under conditions that allow hybridization of the first segment to the target polynucleotide and wherein the second segment is at the 5' of the first segment, wherein the target polynucleotide comprises a biomarker; (b) providing a polymerase, under conditions that permit extension of the target polynucleotide by the polymerase, thereby producing an extended target polynucleotide and the extended target polynucleotide comprises a portion complementary to the first segment and a portion complementary to the second segment; (c) amplifying the extended target polynucleotide using a primer having homology to the 5'-terminus of the target polynucleotide, and determining the nucleotide sequence of all or a portion of the extended target polynucleotide, thereby detecting the presence of the biomarker in the sample. (a) contacting a sample with a template polynucleotide, under conditions whereby a target polynucleotide in the sample hybridizes to the template polynucleotide, wherein the template polynucleotide comprises a first segment that is hybridizable to the target polynucleotide and a second segment that does not hybridize to the target polynucleotide under conditions that allow hybridization of the first segment to the target polynucleotide and wherein the second segment is at the 5' of the first segment, wherein the target polynucleotide comprises a biomarker; (b) providing a polymerase, under conditions that permit extension of the target polynucleotide by the polymerase, thereby producing an extended target polynucleotide and the extended target polynucleotide comprises a portion complementary to the first segment and a portion complementary to the second segment; (c) amplifying the extended target polynucleotide using a primer having homology to the 5'-terminus of the target polynucleotide, and determining the nucleotide sequence of all or a portion of the extended target polynucleotide, thereby detecting the presence of the biomarker in the sample.
A system for evacuating a process space, having a first compressor, which can be coupled via a first inflow line to the process space and from which, via a first outflow line, medium taken from the process space can be discharged into the surroundings, having a second compressor, which via a second inflow line can be coupled to the process space and from which, via a second outflow line, medium taken from the process space can be discharged into the surroundings, having a connecting line connected between the first outflow line and the second inflow line, having a first inflow line valve integrated in the first inflow line, having a second inflow line valve integrated in the second inflow line, having a first outflow line valve integrated in the first outflow line, having a connecting line valve integrated in the connecting line, wherein in particular when the first inflow line valve, the second inflow line valve and the first outflow line valve are all open and the connecting line valve is closed, the first compressor and the second compressor can be operated in parallel, wherein in particular when the first inflow line valve and the connecting line valve are both open and the second inflow line valve and the first outflow line valve are both closed, the first compressor and the second compressor can be operated in series, characterized in that the first inflow line is assigned a first pressure sensor and the second inflow line a second pressure sensor, wherein the second inflow line valve, the first outflow line valve and the connecting line valve can all be controlled dependent on measurement values of the two pressure sensors (31, 32).
A drug delivery system comprising an elongated inert support, and at least two reservoirs (3,8,12,14, 17,19,21,23,29) comprising a pharmaceutically active ingredient, wherein said elongated inert support has a longitudinal axis and comprises a number of wall segments defining at least two compartments arranged longitudinally along the axis of said support, said compartments are arranged for accommodating the at least two reservoirs (3,8,12,14,17,19,21,23,29) and wherein the inert support is made of a material, which substantially prevents migration and/or diffusion of active ingredient from one reservoir into the support and further into at least one neighbouring reservoir, and wherein each reservoir defines a surface area through which the pharmaceutically active ingredient can diffuse/migrate into the surroundings and wherein the surface area of each reservoir does not extend beyond the wall segments of the inert support.
A system comprising: - a carrier fixture (12, 112, 312, 412), the carrier fixture (12, 112, 312, 412) being a monument wall or a partition wall; and - a flight attendant seat (10, 100, 200, 300, 400), comprising: - a frame (14, 114, 214, 314, 414) that is integrated into the carrier fixture (12, 112, 312, 412), and - at least one seat arrangement (22, 320) integrated into the frame (14, 114, 214, 314, 414), wherein the frame (14, 114, 214, 314, 414) comprises a lower section (16, 116, 316), an upper section (20, 220, 320, 420) and a central section (18, 318, 418) taking up the at least one seat arrangement (22, 320) at least partially, wherein the lower section (16, 116, 316, 416) is formed bent at least in a region adjoining the central section (18, 318, 418) and forms the curved part of a U-shape, the lower section (16, 116, 316, 416) forming a support for the flight attendant seat (10, 100, 200, 300, 400) configured to conduct a load into the carrier fixture (12, 112, 312, 412), and wherein the central section (18, 318, 418) forms at least a portion of the substantially straight sides of the U-shape. - a carrier fixture (12, 112, 312, 412), the carrier fixture (12, 112, 312, 412) being a monument wall or a partition wall; and - a flight attendant seat (10, 100, 200, 300, 400), comprising: - a frame (14, 114, 214, 314, 414) that is integrated into the carrier fixture (12, 112, 312, 412), and - at least one seat arrangement (22, 320) integrated into the frame (14, 114, 214, 314, 414), wherein the frame (14, 114, 214, 314, 414) comprises a lower section (16, 116, 316), an upper section (20, 220, 320, 420) and a central section (18, 318, 418) taking up the at least one seat arrangement (22, 320) at least partially, wherein the lower section (16, 116, 316, 416) is formed bent at least in a region adjoining the central section (18, 318, 418) and forms the curved part of a U-shape, the lower section (16, 116, 316, 416) forming a support for the flight attendant seat (10, 100, 200, 300, 400) configured to conduct a load into the carrier fixture (12, 112, 312, 412), and wherein the central section (18, 318, 418) forms at least a portion of the substantially straight sides of the U-shape. wherein the frame (14, 114, 214, 314, 414) comprises a lower section (16, 116, 316), an upper section (20, 220, 320, 420) and a central section (18, 318, 418) taking up the at least one seat arrangement (22, 320) at least partially, wherein the lower section (16, 116, 316, 416) is formed bent at least in a region adjoining the central section (18, 318, 418) and forms the curved part of a U-shape, the lower section (16, 116, 316, 416) forming a support for the flight attendant seat (10, 100, 200, 300, 400) configured to conduct a load into the carrier fixture (12, 112, 312, 412), and wherein the central section (18, 318, 418) forms at least a portion of the substantially straight sides of the U-shape.
A continuously variable valve lift system, comprising a driving swing arm, a camshaft and a valve structure, the valve structure comprising a roller rocker arm and a valve connected to the roller rocker arm, the driving swing arm having a driving arc surface, the driving arc surface contacting with the roller rocker arm to drive the valve to move in a reciprocating manner, wherein the continuously variable valve lift system further comprises a control shaft and an adjusting swing arm, the driving swing arm is sleeved on the control shaft and is capable of swinging around the control shaft, the control shaft is provided with a mounting part, the adjusting swing arm is connected to the mounting part and is capable of swinging relative to the mounting part, the adjusting swing arm is disposed between the camshaft and the driving swing arm, characterized in that the driving swing arm is provided with a first contact surface which faces to the adjusting swing arm, the first contact surface is provided in the middle position of the driving swing arm, the adjusting swing arm is provided with a second contact surface which faces to the driving swing arm, the first contact surface contacts with the second contact surface, such that two sides of the adjusting swing arm are contacted respectively with the camshaft and the driving swing arm.
Hardening accelerator for mineral binder compositions, in particular cementitious binder compositions, containing a combination of a) a first amino alcohol comprising at least one primary alcohol group, and b) a second amino alcohol comprising at least one secondary alcohol group; wherein the first amino alcohol is selected from N-ethyl-diethanolamine (EDEA), N-butyldiethanolamine (BDEA), 2-(diisopropylamino)ethanol, 2-(2-aminoethylamino)ethanol, N,N,N'-trimethylaminoethyl-ethanolamine, N,N'-bis(2-hydroxyethyl)ethylenediamine, N-methyldiethanolamine (MDEA), diethanolamine, 2-amino-2-methyl-1,3-propanediol (AMPD), tris(hydroxymethyl)aminomethane (TRIS), 3-amino-1,2-propanediol and/or 2-(2-aminoethoxy)ethanol. a) a first amino alcohol comprising at least one primary alcohol group, and b) a second amino alcohol comprising at least one secondary alcohol group;
A container for foodstuff, said container comprising a tray formed from a sheet of material comprising one or more layers, where the material of each of the layers of the formed tray comprises at least 85 % of amorphous polyethylene terephthalate, said tray comprising a bottom part, one or more side walls and a peripheral sealing rim at its top, said sealing rim having a substantially flat upward facing sealing surface, wherein, in addition to the material from which the tray is made, the sealing surface is provided with a layer of an adhesive along the full circumference of the tray. a bottom part, one or more side walls and a peripheral sealing rim at its top, said sealing rim having a substantially flat upward facing sealing surface,
A cooling unit compressor system comprising a controller for a cooling unit compressor having two two-phase AC asynchronous motors (K1, K2), the controller comprising mains connection means for connection to a preferably public voltage supply network nominally providing an AC mains voltage between 85 V and 264 V, in particular between 100 V and 230 V, first voltage converter means connected downstream of the mains connection means and serving to generate an intermediate voltage, in particular an intermediate DC voltage, from the AC mains voltage, two second voltage converter means (16-1, 16-2) connected downstream of the first voltage converter means and serving to generate an output signal, in particular a temporarily voltage-constant and/or frequency-constant output signal, which is independent from a level and from a mains frequency of the AC mains voltage and which serves to control the cooling unit compressor with an AC voltage of a plurality of different predeterminable voltage levels, voltage detection means being assigned to the mains connection means, which serve to detect the AC mains voltage and whose detector output signal can be evaluated by the second voltage converter means or by controlling means assigned to them in order to generate a maximum value dependent on the mains voltage for a current of the output signal, the cooling unit compressor system also comprising the cooling unit compressor having two AC asynchronous motors, the second voltage converter means being configured in such a manner that a first one of the AC asynchronous motors is controlled for start-up and/or starting operation when a detected cooling temperature is above a threshold, and the second AC asynchronous motors is controlled only after the temperature has dropped below the threshold, and the second voltage converter means lowering the voltage of the output signal controlling the AC asynchronous motors when a target cooling temperature is detected.
A steering joint comprising: an outer joint member having a ball groove formed in an inner periphery thereof; an inner joint member having a ball groove formed in an outer periphery thereof; a torque transmission ball interposed between the ball groove of the outer joint member and the ball groove of the inner joint member; and a cage for holding the torque transmission ball, wherein the outer joint member and the inner joint member each have male spline shaft (18, 46) for plastic joining, wherein shaft clamps are provided, characterised in that each of the shaft clamps has a connection hole that has a female spline extending from one axial end partway toward the other axial end, and that has no quench-hardened layer formed thereon, and the connection holes having an inner diameter at a portion having no female spline formed therein, being less than an outer diameter of the spline shafts (18, 46), the spline shafts (18, 46) each have an outer periphery having a quench-hardened layer formed thereon, and the spline shafts (18, 46) are press fitted into connection holes of the shaft clamps at portions of the connection holes having an inner diameter that is less than an outer diameter of the spline shafts (18, 46) to plastically join the shaft clamps to the male splines.
Exenatide for use in treating type 2 diabetes mellitus in a subject, wherein the subject is a human, the use comprising: providing continuous delivery of the exenatide from an osmotic delivery device, the exenatide having the amino acid sequence of exendin-4, wherein (i) substantial steady-state delivery of the exenatide at a therapeutic concentration is achieved within a time period selected from the group consisting of 5 days or less, 4 days or less, 3 days or less, 2 days or less, and 1 day or less after implantation of the osmotic delivery device in the human, and (ii) the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least 3 months at a mcg/day dose of exenatide selected from the group consisting of 10 mcg/day, 20 mcg/day, 40 mcg/day, 60 mcg/day and 80 mcg/day; wherein the use further comprises a first continuous administration period of the exenatide at a first mcg/day dose that is followed by a second continuous administration period providing a dose escalation of the exenatide to a second mcg/day dose, wherein the second mcg/day dose is greater than the first mcg/day dose. providing continuous delivery of the exenatide from an osmotic delivery device, the exenatide having the amino acid sequence of exendin-4, wherein (i) substantial steady-state delivery of the exenatide at a therapeutic concentration is achieved within a time period selected from the group consisting of 5 days or less, 4 days or less, 3 days or less, 2 days or less, and 1 day or less after implantation of the osmotic delivery device in the human, and (ii) the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least 3 months at a mcg/day dose of exenatide selected from the group consisting of 10 mcg/day, 20 mcg/day, 40 mcg/day, 60 mcg/day and 80 mcg/day; wherein the use further comprises a first continuous administration period of the exenatide at a first mcg/day dose that is followed by a second continuous administration period providing a dose escalation of the exenatide to a second mcg/day dose, wherein the second mcg/day dose is greater than the first mcg/day dose.
A tampon comprising a pair of longitudinally extending side edges (1010A, 1010B), the tampon further comprising: an absorbent member comprising an insertion area, a withdrawal area, and an intermediate area between the insertion area and the withdrawal area, the absorbent member further comprising an attachment area wherein the attachment area extends from the insertion area to the withdrawal area and absorbent material comprising a plurality of fiber integrated nonwoven layers, characterized in that each of the fiber integrated nonwoven layers are without fiber integration between adjacent layers outboard of the attachment area; and a withdrawal line extending from the withdrawal area and is attached to the absorbent member in the attachment area, wherein each of the plurality of fiber integrated nonwoven layers are attached to an adjacent fiber integrated nonwoven layer in the attachment area wherein each of the nonwoven layers comprises a hydroentangled nonwoven having a basis weight of greater than 75 grams per square meter. an absorbent member comprising an insertion area, a withdrawal area, and an intermediate area between the insertion area and the withdrawal area, the absorbent member further comprising an attachment area wherein the attachment area extends from the insertion area to the withdrawal area and absorbent material comprising a plurality of fiber integrated nonwoven layers, characterized in that each of the fiber integrated nonwoven layers are without fiber integration between adjacent layers outboard of the attachment area; and a withdrawal line extending from the withdrawal area and is attached to the absorbent member in the attachment area, wherein each of the plurality of fiber integrated nonwoven layers are attached to an adjacent fiber integrated nonwoven layer in the attachment area wherein each of the nonwoven layers comprises a hydroentangled nonwoven having a basis weight of greater than 75 grams per square meter.